Abstract
Introduction. Colorectal cancer (CRC) remains one of the leading oncological diseases, the development of which is accompanied by characteristic epigenetic changes. The most significant of these is the hypermethylation of the SEPT9 gene, detected both in tumor tissue and in circulating tumor DNA. This marker demonstrates a close relationship with lymph node damage and metastasis, which determines its value not only for diagnosis, but also for the staging of CRC, increasing the accuracy of risk stratification and the choice of treatment tactics.
The purpose of the study. To study the diagnostic significance of SEPT9 methylation in the blood of patients with CRC and its role in the staging of the tumor process.
Material and methods. The study included 24 patients with newly diagnosed CRC who underwent surgical treatment at Pavlov Moscow State Medical University in 2023-2024. Analysis of SEPT9 methylation in blood plasma was performed using the Real-time PCR-SEPT9-Met kit (BioLink, Russia).
Results. The overall detectability of SEPT9 methylation was 62.5% (15/24). In patients with metastases, the rate was significantly higher –
78.9%. In stages I–II, mSEPT9 was not detected at the current sample size, whereas in stages III–IV, a positive result was determined in 77.8–100% of cases. SEPT9 methylation correlated with lymph node damage: detectability was 85.7% for N1 and 60.0% for N2, absent at N0.
Conclusion. SEPT9 methylation holds significant promise as a biomarker for monitoring CRC metastasis and proper disease staging. Preliminary validation results of mSEPT9 have demonstrated its diagnostic value in the advanced stages of CRC, and its role in the initial stages requires further study.
Authors and affiliations
https://elibrary.ru/fowgvu A.V. Toropova(1), V.D. Nazarov(2), S.V. Lapin(2), A.A. Zakharenko(2), O.A. Ten(2), I.A. Filatova(2),
P.A. Fedorova(2), E.A. Devyatkin(2), M.K. Musonova(2), D.S. Slivinskiy(2), V.A. Nikitina(3)
1-Federal State Budgetary Educational Institution of Higher Education “Saint-Petersburg State Technological Institute (Technical University)”, Moskovsky Avenue, 24–26/49, letter A, 190013, Saint-Petersburg, Russian Federation; 2-Pavlov First Saint-Petersburg State
Medical University, Lva Tolstogo str., 6–8, Saint-Petersburg, 197022, Russian Federation; 3-Federal State Budgetary Scientific Institution
“Institute of Experimental Medicine”, Akademika Pavlova str., 12, Saint-Petersburg, 197376, Russian Federation
References
1. Mármol I., Sánchez-de-Diego C., Pradilla Dieste A., Cerrada E., Rodriguez Yoldi M.J. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. International J. of Molecular Sciences. 2017; 18 (1): 197. https://doi.org/10.3390/ijms18010197
2. Dunne P.D., Arends M.J. Molecular pathological classification of colorectal cancer–an update. Virchows Arch. 2024; 484: 273–85. https://doi.org/10.1007/s00428-024-03746-3
3. Sobanski Thais et al. Methylation profile of colon cancer genes in colorectal precursor lesions and tumor tissue: perspectives for screening. Scandinavian journal of gastroenterology. 2021: 56.8: 920–8. https://doi.org/10.1080/00365521.2021.1922744
4. Tóth K., Wasserkort R., Sipos F., Kalmár A., Wichmann B., Leiszter K. et al. Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA. PLoS ONE. 2014; 9 (12): e115415. https://doi.org/10.1371/journal.pone.0115415
5. Wasserkort R., Kalmar A., Valcz G. et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer. 2013; 13: 398. https://doi.org/10.1186/1471-2407-13-398
6. Sun J., Zheng M.Y., Li Y.W., Zhang S.W. Structure and function of Septin 9 and its role in human malignant tumors. World J. Gastrointest Oncol. 2020; 12 (6): 619–31. https://doi.org/10.4251/wjgo.v12.i6.619
7. Jiao X., Zhang S., Jiao J. et al. Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance. Clin Epigenet. 2019; 11: 120. https://doi.org/10.1186/s13148-019-0719-9
8. Tóth K., Galamb O., Spisák S. et al. The Influence of Methylated Septin 9 Gene on RNA and Protein Level in Colorectal Cancer. Pathol. Oncol. Res. 2011; 17: 503–9. https://doi.org/10.1007/s12253-010-9338-7
9. Sun J., Xu J., Sun C., Zheng M., Li Y., Zhu S., Zhang S. Screening and Prognostic Value of Methylated Septin9 and its Association With Clinicopathological and Molecular Characteristics in Colorectal Cancer. Frontiers in Molecular Biosciences. 2021; 8: 568818. https://doi.org/10.3389/fmolb.2021.568818
10. Marcus J., Bejerano-Sagie M., Patterson N. et al. Septin 9 isoforms promote tumorigenesis in mammary epithelial cells by increasing migration and ECM degradation through metalloproteinase secretion at focal adhesions. Oncogene. 2019; 38: 5839–59. https://doi.org/10.1038/s41388-019-0844-0
11. Li R., Chen J., Shen X., Lin Y., Tang J., Xiong G. et al. A study of the clinical significance of mSEPT9 in monitoring recurrence and prognosis in patients with surgically treated colorectal cancer. Plos one. 2024; 19.10: e0312676. https://doi.org/10.1371/journal.pone.0312676
12. He N., Feng G., Dou J.H. et al. Relationship of DNMT3b expression and SEPT9 methylation in theprogression of colorectal carcinogenesis. Zhonghua Zhong liu za zhi [Chinese Journal of Oncology], 2020; 42 (11): 925–30. https://doi.org/10.3760/cma.j.cn112152-20190408-00223
13. Tóth K., Wasserkort R., Sipos F., Kalmár A., Wichmann B., Leiszter K. et al. Detection of Methylated Septin 9 in Tissue and Plasma of Colorectal Patients with Neoplasia and the Relationship to the Amount of Circulating Cell-Free DNA. PLoS ONE. 2014; 9 (12): e115415. https://doi.org/10.1371/journal.pone.0115415
14. Wasserkort R., Kalmar A., Valcz G. et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer. 2013; 13: 398. https://doi.org/10.1186/1471-2407-13-398
15. Paska A.V., Hudler P. Aberrant methylation patterns in cancer: a clinical view. Biochem Med (Zagreb). 2015; 25: 161–76 https://doi.org/10.11613/BM.2015.017
16. Wieszczy P., Regula J., Kaminski M.F. Adenoma detection rate and risk of colorectal cancer. Best Practice & Research Clinical Gastroenterology. 2017; 31 (4): 441–6. https://doi.org/10.1016/j.bpg.2017.07.002
17. Nagtegaal I.D., Odze R.D., Klimstra D., Paradis V., Rugge M., Schirmacher P., Washington K.M., Carneiro F., Cree I.A. WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76 (2): 182–8. DOI: 10.1111/his.13975.
18. Angelis D., Spiliotis E.T. Septin mutations in human cancers. Frontiers in cell and developmental biology. 2016; 4: 122. https://doi.org/10.3389/fcell.2016.00122
19. Dimo Dietrich, Simone Weider, Luka de Vos, Timo Jakob Vogt, Moritz Färber, Romina Zarbl, Alina Hunecke, Ann-Kathrin Glosch, Jennis Gabrielpillai, Friedrich Bootz, Franz-Georg Bauernfeind, Franz-Josef Kramer, Glen Kristiansen, Peter Brossart, Sebastian Strieth, Alina Franzen, Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients, Clinical Chemistry. 2023; 69 (9): 1050–61. https://doi.org/10.1093/clinchem/hvad084
20. Xiao Han, Junyun Wang, Yingli Sun, Circulating Tumor DNA as Biomarkers for Cancer Detection, Genomics, Proteomics & Bioinformatics. 2017; 15 (2): 59–72. https://doi.org/10.1016/j.gpb.2016.12.004
21. Shames, David S., John D. Minna, and Adi F. Gazdar. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer letters. 2007; 251.2: 187–98. https://doi.org/10.1016/j.canlet.2006.10.014
22. Timothy R. Church; Michael Wandell; Catherine Lofton–Day; Steve Mongin; Brent A. Blumenstein; John I. Allen; Thomas Roesch; Dale Snover; Robert Day; David F. Ransohoff. Prospective Clinical Validation of an Assay for Methylated SEPT9 DNA in Human Plasma as a Colorectal Cancer Screening Tool in Average Risk Men and Women ≥50 Years. Gastroenterology. 2010; 139.1: e18. https://doi.org/10.1053/j.gastro.2010.05.068
23. Peng Jin, Qian Kang, Xin Wang, Lang Yang, Yang Yu, Na Li, Yu-qi He, Xiaoliang Han, Jie Hang, Jing Zhang, Lele Song, Ying Han, Jian-qiu Sheng. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. Journal of gastroenterology and hepatology. 2015; 30 (5): 830–3. https://doi.org/10.1111/jgh.12855
24. Song L., Li Y., Jia J., Zhou G., Wang J., Kang Q. et al. Algorithm Optimization in Methylation Detection with Multiple RT-qPCR. PLoS ONE. 2016; 11 (11): e0163333. https://doi.org/10.1371/journal.pone.0163333
25. Williams, Christina D., William M. Grady, and Leah L. Zullig. Use of NCCN guidelines, other guidelines, and biomarkers for colorectal cancer screening. Journal of the National Comprehensive Cancer Network. 2016; 14.11: 1479–85. https://doi.org/10.6004/jnccn.2016.0154
26. Song L., Jia J., Peng X. et al. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci Rep. 2017; 7: 3032. https://doi.org/10.1038/s41598-017-03321-8
27. Sun J., Fei F., Zhang M. et al. The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer. 2019; 19: 450. https://doi.org/10.1186/s12885-019-5663-8
28. Chen Z.-G., Ji X.-M., Xu Y.-X. et al. Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases. Therapeutic Advances in Medical Oncology. 2024; 16. DOI: 10.1177/17588359241230752
29. Lima A.B., Dos Reis M.B., Matsushita M., Dos Reis M.T., de Oliveira M.A., Reis R.M., Guimarães D.P. Combined SEPT9 and BMP3 methylation in plasma for colorectal cancer early detection and screening in a Brazilian population. Cancer Med. 2023; 12 (15): 15854–67. DOI: 10.1002/cam4.6224
30. Wu D., Zhou G., Jin P., Zhu J., Li S., Wu Q., Qian, J. Detection of colorectal cancer using a simplified SEPT9 gene methylation assay is a reliable method for opportunistic screening. The Journal of Molecular Diagnostics. 2016; 18 (4): 535–45. http://dx.doi.org/10.1016/j.jmoldx.2016.02.005
31. He N., Song L., Kang Q. et al. The Pathological Features of Colorectal Cancer Determine the Detection Performance on Blood ctDNA. Technology in Cancer Research & Treatment. 2018; 17. DOI: 10.1177/1533033818791794
32. Theo deVos, Reimo Tetzner, Fabian Model, Gunter Weiss, Matthias Schuster, Jurgen Distler, Kathryn V Steiger, Robert Grutzmann, Christian Pilarsky, Jens K Habermann, Phillip R Fleshner, Benton M Oubre, Robert Day, Andrew Z Sledziewski, Catherine Lofton-Day, Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal Cancer, Clinical Chemistry. 2009; 55 (7): 1337–46. https://doi.org/10.1373/clinchem.2008.115808
33. Xie L., Jiang X., Li Q., Sun Z., Quan W., Duan Y., Li D., Chen T. Diagnostic Value of Methylated Septin9 for Colorectal Cancer Detection. Front Oncol. 2018; 8: 247. DOI: 10.3389/fonc.2018.00247
34. Nian J., Sun X., Ming S., Yan C., Ma Y., Feng Y., Yang L., Yu M., Zhang G., Wang X. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2017; 8 (1): e216. DOI: 10.1038/ctg.2016.66
35. Catherine Lofton-Day, Fabian Model, Theo DeVos, Reimo Tetzner, Juergen Distler, Matthias Schuster, Xiaoling Song, Ralf Lesche, Volker Liebenberg, Matthias Ebert, Bela Molnar, Robert Grutzmann, Christian Pilarsky, Andrew Sledziewski, DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening, Clinical Chemistry. 2008; 54 (2): 414–23. https://doi.org/10.1373/clinchem.2007.095992
36. Huang M., He J., Lai W. et al. Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery. BMC Gastroenterol. 2022; 22: 87. https://doi.org/10.1186/s12876-022-02172-6